Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 49

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 49
---
 ended June 30, 2025, the Company sold 75,064
common shares of the Company for net proceeds of $481,971 under the November 2024 Keystone Purchase Agreement.

Issuance
of Common Stock to Arena Business Solutions Global SPC II, Ltd. (“Arena”) for the Arena ELOC

On
February 23, 2024, the Company entered into a common stock purchase agreement (the “Arena Purchase Agreement”) with Arena,
pursuant to which we may sell and issue, and Arena is obligated to purchase, up to $25,000,000 of Common Stock. The price of the shares
purchased by Arena under the ELOC is 90% of various VWAP and closing price-based formulae, and requires a waiver, should the selling
price be below $500.00 per share. As consideration for Arena commitment to purchase shares of Common Stock pursuant to the Arena Purchase
Agreement, in May 2024, the Company issued 173 shares of Common Stock to Arena valued at $500,000, which is reflected as deferred offering
costs on the accompanying consolidated balance sheet as of June 30, 2025 and December 31, 2024. The Company has sold no shares of Common
Stock to Arena under the Arena ELOC during the six months ended June 30, 2025 and 2024.

Sale
of Pre-funded Warrants and Common Stock

On February 5, 2025, the Company announced the pricing of a reasonable
best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors
and a single institutional investor, for the purchase and sale of (i) 127,551 shares of its common stock, par value $0.0001 per share
(the “Common Stock”) or common stock equivalents in lieu thereof (the Company sold 15,000 shares of its common stock and 112,551
pre-funded warrants); and (ii) common warrants to purchase up to 127,551 shares of common stock (the “Warrants”), at a combined
public offering price of $39.20 per share and Warrant. In connection with the Offering, on February 5, 2025, the Company entered into
a securities purchase agreement (the “SPA”) with the investors. The SPA contains customary representations, warranties and
agreements of the Company and each investor and customary indemnification rights and obligations of the parties. In connection